摘要
目的:探讨二氢嘧啶脱氢酶基因(DPYD)的T85C和A1627G突变对浸润性乳腺癌患者生存的影响。方法:采用SPSS19.0软件进行统计学分析,使用临床资料完整的173例浸润性乳腺癌患者的石蜡包埋组织标本,检测并分析了DPYD基因编码序列的第85位点和第1627位点的核苷酸突变情况,并分析其与患者预后的关系。结果:T85C和A1627G位点联合突变与患者的淋巴结转移状态呈正相关。T85C和A1627G位点单突变对乳腺癌患者预后无影响,而与对照组相比,存在T85C和A1627G位点联合突变的乳腺癌患者预后较差,差异具有统计学意义。结论:中国乳腺癌患者中,DPYD基因T85C和A1627G联合突变与患者的淋巴结转移状态相关,T85C和A1627G联合突变的患者预后较差。
Objective： To explore the prognostic effect of two mutations, T85C and A1627G of dihydropyrimidine dehydrogenase （DPYD） gene in invasive breast cancer. Methods： Paraffin-embedded specimens of 173 invasive breast cancer patients were sequenced and the nucleotide mutations at 85 and 1627 locus of DPYD gene coding sequence were detected. SPSS 19.0 software package was used to analysis the relationship between these two mutations and patients＇ prognosis. Results： T85C combined with A1627G mutations showed a positive association with lymph node metastasis in breast cancer patients. T85C or A1627G single mutation was not correlated with prognosis of breast cancer patients. Patients with both T85C and A1627G mutations showed a worse prognosis compared with other patients. Conclusion： Combination of T85C with A1627G mutations in DPYD may have a positive association with lymph metastasis in Chinese invasive breast cancer patients. T85C combined with A 1627G mutations indicates a worse prognosis.
出处
《天津医科大学学报》
2016年第5期412-416,共5页
Journal of Tianjin Medical University
基金
国家自然科学基金资助项目(81272358)
关键词
乳腺癌
二氢嘧啶脱氢酶基因
突变
预后
breast cancer
dihydropyfimidine dehydrogenase gene
mutation
prognosis
